Loading organizations...
Loading organizations...
Based in Zurich, Switzerland, ENANTIOS develops high-precision measurement instruments and measurement-as-a-service solutions that analyze the structure of complex chiral molecules and biologics using Raman Optical Activity technology. The deeptech company provides its molecular screening and quality control testing systems directly to pharmaceutical developers, biotechnology firms, chemical manufacturers, and academic research institutions. Operating with approximately four employees, the enterprise recently transitioned from a service provider to a product manufacturer by delivering its first physical measurement instrument to a commercial customer in April 2025. To support its ongoing hardware development and strategic hiring initiatives, ENANTIOS has raised $2.5 million in total funding, including a seed round led by Privilège Ventures with participation from Zürcher Kantonalbank and S2S Ventures. The organization was founded in 2022 as a spin-off from ETH Zurich by co-founders Carin Lightner and Roman Wyss.
ENANTIOS has raised $2.0M across 1 funding round.
ENANTIOS has raised $2.0M in total across 1 funding round.
ENANTIOS has raised $2.0M in total across 1 funding round.
ENANTIOS's investors include Privilège Ventures, Beat Schillig.
Enantios AG is a Swiss biotechnology company that develops advanced measurement platforms and services for the structural analysis of complex biologics and chiral molecules, accelerating drug discovery and quality control in pharmaceuticals.[1][2][3] Their core products include Raman Optical Activity (ROA) spectrometers and "Measurement as a Service," enabling chirality confirmation, conformational analysis, and non-destructive testing without chiral-HPLC, crystallization, or purified standards—serving pharma researchers, CROs, and CMOs in academia and industry.[1][3][4] As a young spin-off, Enantios shows early momentum through participation in major events like BIO International Convention 2025 and CPHI Frankfurt 2025, focusing on applications like antibody-drug conjugates (ADCs) and targeted protein degraders (LDDs).[1][4]
Enantios was founded in December 2022 as a spin-off from ETH Zürich, leveraging proprietary ROA technology developed there for pharmaceutical characterization.[2][3] The team, based in Zurich, Switzerland, is small (1-24 employees) and dedicated to innovation in biotech analytics, led by CEO Dr. Carin Lightner, who represents the company at industry conventions.[1][4] The idea emerged from gaps in traditional tools—despite advances in complex drugs, characterization methods lagged, slowing discovery and raising costs—prompting the creation of compact, user-friendly ROA instruments that fit into glove boxes and simplify workflows.[2][3] Early traction includes offering proof-of-concept services and instruments, with a focus on enabling next-generation medicines through Swiss precision engineering.[2][5]
Enantios stands out in biotech analytics through these key strengths:
Enantios rides the wave of advanced therapeutics like ADCs, LDDs, and biologics, where precise chirality and conformational data are critical yet bottlenecked by outdated tools.[1][3] Timing aligns with surging demand for faster drug development amid rising manufacturing costs and regulatory scrutiny on molecular purity.[2][5] Market forces favoring them include biotech's shift to complex modalities (e.g., non-crystalline biologics) and the need for scalable QC, positioning Enantios to cut discovery timelines and enable quality testing at scale.[3][5] They influence the ecosystem by democratizing high-precision analytics, supporting CROs/CMOs, and fostering pharma-academia ties through ETH origins and events like BIO/CPHI.[1][4]
Enantios is poised for growth by expanding ROA adoption in ADC/LDD pipelines and scaling services to more biologics, potentially partnering with big pharma for in-house integration.[1][3] Trends like AI-driven drug design and sustainable manufacturing will amplify their edge in rapid, green analytics, while global events signal inbound traction.[1][4] Their influence may evolve from niche innovator to standard tool in chiral characterization, humanizing biotech progress through accessible tech that unlocks complex molecules—ultimately speeding therapies that improve lives.[2][3]
ENANTIOS has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $2.0M Seed | Privilège Ventures | Beat Schillig |